the aid library

LIST OPTIONS

Filter

10531

Sort by:

Direction:

Download (168)

View PDF (391)

Epilepsy in the Western Pacific Region - A call to action

World Health Organization (WHO) (2004) C_WHO

Global Campaign Against Epilepsy

Download (1161)

View PDF (2332)

Guidelines for the inpatient treatment of severely malnourished children

Ann Ashworth et al. World Health Organization (2003)

Download (227)

View PDF (429)

Caring for children and adolescents with mental disorders

World Health Organization WHO (2003) C_WHO

Setting WHO directions

Download (172)

View PDF (164)

Planning and implementing palliative care services: a guide for programme managers

World Health Organization WHO (2016) C_WHO

Download (70)

View PDF (281)

Conceptual and Operational Framework of Onchocerciasis Elimination with Ivermectin Treatment

World Health Organization WHO; African Programme for Onchocerciasis Control APOC (2010) C_WHO

Onchocerciasis used to be an important public health problem in Africa, with over 37 million people infected and millions suffering from debilitating skin disease, terrible itching, impaired vision and blindness. But the epidemiological situation has improved dramatically over the last two decades.... more

Download (243)

View PDF (278)

Technical handbook for dengue surveillance, dengue outbreak prediction/detection and outbreak response (“model contingency plan”)

World Health Organization WHO; TDR Program (2017) C_WHO

The aim of this “model contingency plan” is to assist programme managers and planners in devel-oping a national, context-specific, dengue outbreak response plan in order to: (a) detect a dengue outbreak at an early stage through clearly defined and validated alarm signals; (b) precisely define w... more

Download (390)

View PDF (706)

Global influenza strategy 2019-2030

World Health Organization WHO (2019) C_WHO

The goal of the strategy is to prevent seasonal influenza, control the spread of influenza from animals to humans, and prepare for the next influenza pandemic. The new strategy is the most comprehensive and far-reaching that WHO has ever developed for influenza. It outlines a path to protect popul... more

Download (504)

View PDF (1398)

Operational Manual – Global Leprosy Strategy 2016−2020

Cooreman, E.A. World Health Organization WHO, SEARODepartment of Control of Neglected Tropical Diseases (2016) C_WHO

Accelerating towards a leprosy-free world

Download (1359)

View PDF (2135)

Effective communications: participant handbook for WHO staff

World Health Organization WHO (2015) C_WHO

Download (1223)

View PDF (2258)

Standard operating procedures for controlling Ebola and Marburg virus epidemics

World Health Organization (2014)

Provisional recommendations May 2014

Download (501)

View PDF (716)

Namibia: STANDARD GUIDELINES ON INFECTION PREVENTION CONTROL IN DENTAL SURGERY

Ministry of Health and Social Services (MOHSS) (2012) C1

Oral Health and Dental Services

Download (719)

View PDF (1184)

Guide for local adaptation - Guidelines for an Integrated Approach to the Nutritional care of HIV-infected children (6 months-14 years)

World Health Organization WHO (2009)

In the area of nutrition and HIV, children deserve special attention because of their additional needs to ensure growth and development and their dependency on adults for adequate care. It was therefore proposed to first develop guidelines for children and thereafter consider a similar approach for... more

Download (8)

View PDF (39)

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe... more

Download (11)

View PDF (14)

Guidelines for the prevention, management and care of diabetes mellitus

World Health Organization WHO (2006) C_WHO

Diabetes mellitus is one of the most common noncommunicable diseases worldwide. In the Eastern Mediterranean Region there has been a rapid increase in the incidence of diabetes mellitus and it is now the fourth leading cause of death. The increasing prevalence of diabetes mellitus, the emergence of ... more

Download (10)

View PDF (8)

SEAHEARTS Monitoring Framework

World Health Organisation (WHO) (2024) C_WHO

Monitoring Framework

Download (19)

View PDF (156)

Global tuberculosis report 2024

World Health Organisation (WHO) (2024) C_WHO

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

Download (78)

View PDF (89)

ACT-A - Urgent Priorities & Financing Requirements at 10 November 2020

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2020) CC

Six months after its launch on 24 April, the Access to COVID-19 Tools (ACT) Accelerator has already delivered concrete results in speeding up the development of new therapeutics, diagnostics, and vaccines. Now mid-way through the scale-up phase, the tools we need to fundamentally change the course o... more

Download (206)

View PDF (110)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

Download (247)

View PDF (333)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (211)

View PDF (187)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more